glpg5101
Generic: Autologous Anti-CD19 CAR T-cells GLPG5101
glpg5101: 1 clinical trial tracked.
glpg5101 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about glpg5101, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A Phase I/II, Multicenter Study Evaluating the Feasibility, Safety, and Efficacy of Point-of-care Manufactured GLPG5101 (19CP02) in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Primary endpoint: Phase 1: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Interventionalopen130 enrolledStarted 2022-03Completion 2026-0511 sites · Belgium, Finland, Netherlands, United StatesLakefront Biotherapeutics NV